| Budget Amount *help |
¥20,280,000 (Direct Cost: ¥15,600,000、Indirect Cost: ¥4,680,000)
Fiscal Year 2017: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2015: ¥10,920,000 (Direct Cost: ¥8,400,000、Indirect Cost: ¥2,520,000)
|
|---|
| Outline of Final Research Achievements |
Emergence of multidrug-resistant bacteria is becoming a major clinical threat. To overcome the problem of multidrug-resistant bacteria, it needs to develop new antibacterial agents and treatment. In this study, we aimed to develop new agents targeting for antibiotic resistance proteins produced in bacteria. Inhibition of antibiotic resistance mechanism by chemical compounds is expected to revive the efficacy of already-existing antibiotics. We targeted metallo-beta-lactamases and 16S rRNA methyltransferases, which are involved in carbapenem and aminoglycoside resistance, respectively. we screened for chemical compounds using in silico and in vitro techniques and identified several inhibitor candidates of metallo-beta-lactamases and 16S rRNA methyltransferases.
|
